# Ulrich Beuers

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ulrich-beuers/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,180 |
| Field | Liver Diseases and Immunity |
| h-index | 100 |
| i10-index | 327 |
| OpenAlex ID | https://openalex.org/A5018461629 |
| ORCID iD | https://orcid.org/0000-0001-5114-7799 |
| Works | 698 |

## Researcher papers

- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-3/)
- [A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis](https://scholariq.org/papers/a-placebo-controlled-trial-of-obeticholic-acid-in-primary-biliary-cholangitis/)
- [Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening](https://scholariq.org/papers/elafibranor-an-agonist-of-the-peroxisome-proliferator-activated-receptor-and/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-2/)
- [Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis](https://scholariq.org/papers/population-based-epidemiology-malignancy-risk-and-outcome-of-primary-sclerosing/)
- [Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis](https://scholariq.org/papers/patient-age-sex-and-inflammatory-bowel-disease-phenotype-associate-with-course/)
- [European Guideline on IgG4‐related digestive disease – UEG and SGF evidence‐based recommendations](https://scholariq.org/papers/european-guideline-on-igg4-related-digestive-disease-ueg-and-sgf-evidence-based/)
- [Microbiome-derived ethanol in nonalcoholic fatty liver disease](https://scholariq.org/papers/microbiome-derived-ethanol-in-nonalcoholic-fatty-liver-disease/)

## Researcher topics

- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Drug Transport and Resistance Mechanisms](https://scholariq.org/topics/drug-transport-and-resistance-mechanisms/)
- [Pediatric Hepatobiliary Diseases and Treatments](https://scholariq.org/topics/pediatric-hepatobiliary-diseases-and-treatments/)
- [Gallbladder and Bile Duct Disorders](https://scholariq.org/topics/gallbladder-and-bile-duct-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.